Navigation Links
Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
Date:11/9/2007

are expected in the second half of 2008.

Pharmion recently initiated an international pivotal Phase 3 trial of Amrubicin versus topotecan as second-line treatment of small cell lung cancer (sensitive or refractory and limited or extensive disease). The randomized, controlled, multi-center study will compare Amrubicin to topotecan, the only approved chemotherapy for second-line treatment of SCLC in the US and EU. The primary endpoint of the study is overall survival. Enrollment in the study of 480 patients is underway. Pharmion has completed the Scientific Advice (SA) process with the European Medicines Agency (EMEA) and has reached Special Protocol Assessment (SPA) agreement with the US Food and Drug Administration (FDA) for the Amrubicin Phase 3 SCLC study.

About Amrubicin

Pharmion acquired the rights to Amrubicin in November 2006 through its acquisition of Cabrellis Pharmaceuticals. In 2002, Amrubicin was approved and launched for sale in Japan based on Phase 2 efficacy data in both SCLC and NSCLC. Since January 2005, Amrubicin has been marketed by Nippon Kayaku, a Japanese pharmaceutical firm focused on oncology, which licensed Japanese marketing rights from Dainippon Sumitomo, the original developer of Amrubicin.

About Small Cell Lung Cancer

Small cell lung cancer is a disease in which malignant cells form in the tissues of the lung, and which occurs almost exclusively in people who smoke. While small cell lung cancer constitutes approximately 15 percent of all lung cancers, SCLC tends to be more aggressive and fast growing than the more common non-small cell lung cancer. Of the estimated 62,000 patients diagnosed with SCLC each year in the US and EU, approximately 60 percent of patients have extensive disease at diagnosis, and the remaining 40 percent present with localized, or limited stage, disease.

About Pharmion

Pharmion is a leading global oncology company uniquely focused on acquiring, developing and commercializi
'/>"/>

SOURCE Pharmion Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
4. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
5. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
6. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
7. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
8. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
9. Feeling Anxious or Distracted? New Research Shows a Cup of Tea Could Help
10. New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
11. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... 27, 2015 Techpool Bio-Pharma Co has experienced tremendous ... its new chief executive officer, transforming from a traditional private ... Henry Lee took office in 2011, he was the ... including Novartis and Eisai, with more than 20 years successful ... the Asia-Pacific region. "I ...
(Date:4/27/2015)... Ga., April 27, 2015  MiMedx Group, Inc. ... company utilizing human amniotic tissue and patent-protected processes ... for the Wound Care, Surgical, Orthopedic, Spine, Sports ... today its record results for the first quarter ... announced today the decision of its Board of ...
(Date:4/27/2015)... April 27, 2015  Consumer Watchdog today applauded ... that requires prescribers to check a state database ... OxyContin and other opioids – to help prevent ... SB 482, authored by Sen. ... , will require prescribers to check Controlled Substance ...
Breaking Medicine Technology:Techpool Transforms Into International Player 2Techpool Transforms Into International Player 3MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 2MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 3MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 4MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 5MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 6MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 7MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 8MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 9MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 10MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 11MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 12MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 13MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 14Consumer Watchdog Praises Passage of Bill that Requires Physicians Check Prescription Drug Database Before Prescribing Powerful, Addictive Medications 2Consumer Watchdog Praises Passage of Bill that Requires Physicians Check Prescription Drug Database Before Prescribing Powerful, Addictive Medications 3
... Therapeutics, Inc. (Nasdaq: OREX ) today announced the ... consisted of one share of common stock and a warrant ... to the public of $1.45 per share of common stock ... stock, which together comprised the purchase price of $15.94 per ...
... organizations, community leaders, health care professionals, and people of ... today urged Express Scripts to get back to the ... access to pharmacy services for hundreds of millions of ... put the people of our communities at the forefront ...
Cached Medicine Technology:Orexigen® Therapeutics Completes Public Offering of Common Stock and Warrants to Purchase Common Stock 2Over 130 Community Leaders and Organizations Across the Nation Urge Express Scripts To Reach Agreement With Walgreens 2
(Date:4/27/2015)... Churchview Supportive Living, a Gardant affordable ... and Fashion Show from 10:30 a.m. to noon on ... 2626 W. 63rd St. in Chicago, serves low-income older ... to maintain their independence. , “Mothers, grandmothers, godmothers and ... Day Brunch,” said Director of Marketing Elizabeth Clippard. , ...
(Date:4/27/2015)... Church, VA (PRWEB) April 28, 2015 ... Works, **Presented by FDAnews and Ombu Enterprises**, June 16-17, ... If an FDA inspector came to a facility today, ... , If the answer is "maybe" or "no" ... Ombu Enterprises and FDAnews have a solution. , ...
(Date:4/27/2015)... 2015 How to Implement UDI:, Lessons ... 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/HowToImplementUDI ... of regulatory restraint, there’s plenty of time to get ... again. UDI deadlines are coming fast for all devicemakers ... Don’t delay, even if it seems there’s no rush. ...
(Date:4/27/2015)... April 28, 2015 Healthcare marketing ... paper called “Website Anatomy 101.” Available ... the necessary design elements for a successful hospital ... responsive design, user experience, search results and lead ... of a well-designed website on patient volume and ...
(Date:4/27/2015)... 2015 Women may have a more ... to a new study published online in the journal ... injury (MTBI), is a common medical problem affecting cognitive ... , In most cases, patients who experience MTBI will ... percent of MTBI patients will continue to experience persistent ...
Breaking Medicine News(10 mins):Health News:Churchview Supportive Living Community in Chicago to Host Mother's Day Brunch 2Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 2Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 3Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 4Health News:FDAnews Announces: How to Implement UDI: Lessons from Early Adopters Webinar, May 20, 2015 2Health News:FDAnews Announces: How to Implement UDI: Lessons from Early Adopters Webinar, May 20, 2015 3Health News:Smith & Jones Publishes 2015 Website Design White Paper 2Health News:Women Show Persistent Memory Impairment after Concussion 2Health News:Women Show Persistent Memory Impairment after Concussion 3
... 3 America,s oldest voluntary health organization is led ... Elected National Board Chair, after more than a decade ... successfully steered the American Lung Association to tackle key ... of his chairmanship has been to build on the ...
... variation in exposure, depending on several factors, , , TUESDAY, ... widely among people who undergo computed tomography (CT) scans, ... in the Feb. 4 issue of the Journal ... after the American Heart Association urged that CT scans ...
... for Southeastern Michigan Screens Patients DETROIT, Feb. 3 ... Saturday, February 7, over 300 children from the Detroit ... of the American Dental Association,s seventh annual "Give Kids ... their services that day to children who, because of ...
... Reinforce Commitment to Safety Net Partnerships and Quality ... Kaiser Permanente announced today that ... totaling approximately $43 million in the fourth quarter ... Community Benefit grants in the fourth quarter focused ...
... Feb. 3 Nearly three out ... insurance should cover the cost of addiction treatment ... their own health insurance would pay for substance ... Toward Addiction Survey" from Hazelden, the national nonprofit ...
... NASHVILLE, Tenn., Feb. 3 Healthcare Realty Trust,Incorporated (NYSE: ... cash dividend for the,quarter ended December 31, 2008. ... payable on March 5, 2009 to shareholders of record ... Realty Trust is a real estate investment trust that ...
Cached Medicine News:Health News:Maryland Lawyer Steve Nolan Advocates for Lung Health as National Board Chair of the American Lung Association 2Health News:Radiation From CT Scans Not Always the Same 2Health News:Radiation From CT Scans Not Always the Same 3Health News:Area Dentists, University of Detroit Mercy Team Up to Provide Free Dental Care to Low-Income, Uninsured Detroit-Area Children on Saturday, February 7 2Health News:Kaiser Permanente Approves $43 Million in Community Benefit Grants in Fourth Quarter 2008 2Health News:Kaiser Permanente Approves $43 Million in Community Benefit Grants in Fourth Quarter 2008 3Health News:Kaiser Permanente Approves $43 Million in Community Benefit Grants in Fourth Quarter 2008 4Health News:Three-Quarters of Americans Believe Health Insurance Should Pay for Addiction Treatment, Yet Most Don't Know If Their Health Plan Covers Substance-Abuse Care, Says New Hazelden Survey 2Health News:Three-Quarters of Americans Believe Health Insurance Should Pay for Addiction Treatment, Yet Most Don't Know If Their Health Plan Covers Substance-Abuse Care, Says New Hazelden Survey 3Health News:Three-Quarters of Americans Believe Health Insurance Should Pay for Addiction Treatment, Yet Most Don't Know If Their Health Plan Covers Substance-Abuse Care, Says New Hazelden Survey 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: